Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment

NCT ID: NCT04698174

Last Updated: 2022-10-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-02

Study Completion Date

2022-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, comparative, randomized, controlled, single-blind, single-surgeon, single-center PMCF clinical study whereby participants undergoing refractive surgery for correction of ametropia will receive a transepithelial PRK (tPRK) and conventional PRK treatment in the contralateral eye. To avoid bias in the clinical outcomes, the two PRK treatment options are randomized to the eyes of the patients based on ocular dominance. In addition, a 1:1 randomization is applied within the tPRK group to eyes with and without end-treatment laser polishing.

Both procedures, standard PRK and tPRK, are performed in a one-step procedure. The main difference between the procedures is, that in conventional PRK, the epithelium will be removed using alcohol, whereas in tPRK procedures, the epithelium will be removed by laser ablation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ametropia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transepithelial Photorefractive keratectomy (tPRK) without laser polishing

Group Type EXPERIMENTAL

Transepithelial Photorefractive keratectomy (tPRK) without laser polishing

Intervention Type PROCEDURE

Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.

Transepithelial Photorefractive keratectomy (tPRK) with laser polishing

Group Type EXPERIMENTAL

Transepithelial Photorefractive keratectomy (tPRK) with laser polishing

Intervention Type PROCEDURE

Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.

Standard Photorefractive keratectomy (PRK)

Group Type ACTIVE_COMPARATOR

Standard Photorefractive keratectomy (PRK)

Intervention Type PROCEDURE

Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transepithelial Photorefractive keratectomy (tPRK) without laser polishing

Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.

Intervention Type PROCEDURE

Transepithelial Photorefractive keratectomy (tPRK) with laser polishing

Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.

Intervention Type PROCEDURE

Standard Photorefractive keratectomy (PRK)

Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ametropia
* Myopic subjects with refractive spherical equivalent (MRSE) between -1.5D and -9.0D
* Hyperopic subjects with refractive spherical equivalent (MRSE) between +1.5D and +5.25D
* Signed informed consent form

Exclusion Criteria

* Ocular comorbidity
* Subject taking systemic medications likely to affect wound healing such as corticosteroids or antimetabolites.
* Subjects who are known to be pregnant, lactating, or who plans to become pregnant over the medications used for standard tPRK.
* Subjects participating in any other ophthalmic clinical trial during this clinical study.
* Subjects with cognitive impairments or other vulnerable persons
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch & Lomb Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Ang, MD

Role: PRINCIPAL_INVESTIGATOR

Asian Eye Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Asian Eye Institute

Makati City, , Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Philippines

References

Explore related publications, articles, or registry entries linked to this study.

Ang RET. Transepithelial Versus Conventional PRK: A Randomized Controlled Study. Ophthalmol Ther. 2025 Jul;14(7):1567-1579. doi: 10.1007/s40123-025-01167-2. Epub 2025 May 30.

Reference Type DERIVED
PMID: 40445504 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BL1902

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.